Synthace Ltd., a London, UK-based provider of a cloud software platform for automating and improving the success rate of biological research and development, closed a $25.6m Series B financing.
The round was led by Horizons Ventures with participation from Luminous Ventures, SOSV and select other individual and large family office investors.
The company will use the new funds for continued product development and build upon its cell and gene therapy customer base to accelerate global awareness of its solutions.
Led by CEO Tim Fell, Synthace is developing Antha, a language and software platform specifically for biology, which makes reproducible and scalable workflows that can be readily edited and shared, and automated on labs’ existing equipment.
The company leverages “Computer Aided Biology”, a new paradigm that comprises Digital and Physical domains.
The Digital, powered by artificial intelligence, includes software for designing and simulating biological systems, as well as methods of collating, structuring and analysing experimental data.
The Physical, enabled by automation, includes systems that allow for the seamless transfer of biological designs into real ‘wet lab’ experiments via logistics simulation and execution.